<?xml version="1.0" encoding="UTF-8"?>
<p>In a drug screen of 2177 compounds against the flavivirus Zika, AZM reduced viral proliferation and virus‐induced cytopathic effects in glial cell lines and human astrocytes.
 <xref rid="rmv2163-bib-0011" ref-type="ref">
  <sup>11</sup>
 </xref> A further in vitro study found AZM to effectively suppress Zika infection by targeting a late stage in the viral life cycle.
 <xref rid="rmv2163-bib-0012" ref-type="ref">
  <sup>12</sup>
 </xref> AZM also upregulated expression of type I and III IFNs and several of their downstream ISGs, paralleling activities of AZM in RV.
 <xref rid="rmv2163-bib-0007" ref-type="ref">
  <sup>7</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0008" ref-type="ref">
  <sup>8</sup>
 </xref> Furthermore, AZM induced enhanced expression of the anti‐viral pattern recognition receptors (PRRs) MDA5 and RIG‐1, as well as the levels of phosphorylated TBK1 and IRF3.
</p>
